Table 2.

Treatment-emergent adverse events (TEAEs)

	1.5% Ruxolitinib cream (n = 41)
Patients with a TEAE, n (%)	13 (31.7)
TEAEs in ≥  1 patient, n (%) [duration, days]
Grade 1
Aspartate aminotransferase increased	2 (4.9) [16, 16]
Upper respiratory tract infection	2 (4.9) [4, 11]
Alanine aminotransferase increased	1 (2.4) [16]
Bronchitis	1 (2.4) [21]
Burns first degree	1 (2.4) [22]
Constipation	1 (2.4) [3]
Cough	1 (2.4) [1]
Headache	1 (2.4) [1]
Liver function test increased	1 (2.4) [14]
Madarosis	1 (2.4) [12]
Muscle strain	1 (2.4) [12]
Nausea	1 (2.4) [1]
Neutropeniaa	1 (2.4) [21]
Pruritus	1 (2.4)b
Rash	1 (2.4) [16]
Restlessness	1 (2.4)b
Rhinitis allergic	1 (2.4) [8]
Seasonal allergy	1 (2.4) [4]
Skin hyperpigmentation	1 (2.4)b
Toothache	1 (2.4) [NA]
Grade 2
Dyspnea	1 (2.4) [15]
Hemoglobin decreasedc	1 (2.4) [45]
Hyperkalemia	1 (2.4) [28]
Grade 3
Limb abscess	1 (2.4) [24]
Patients with treatment-related AE, n (%)	4 (9.8)
Serious TEAE, n (%)	1 (2.4)
Discontinuation because of a TEAE, n (%)	1 (2.4)
Treatment interruption because of a TEAE, n (%)	3 (7.3)

AE adverse event, NA not available

^aNeutrophil count at baseline, 1.06 × 10⁹/L; neutrophil count on day 26, 1.12 × 10⁹/L; range of plasma ruxolitinib, below limit of quantitation to 3.7 nM

^bOngoing at end of study

^cHemoglobin level at baseline, 110 g/L; hemoglobin level at day 41, 90 g/L; range of plasma ruxolitinib, below limit of quantitation to 67.9 nM